Article
AAV9-mediated central nervous system–targeted gene delivery via cisterna magna route in mice
1 Jan 2016
Abstract excerpt
Current barriers to the use of adeno-associated virus serotype 9 (AAV9) in clinical trials for treating neurological disorders are its high expression in many off-target tissues such as liver and heart, and lack of cell specificity within the central nervous system (CNS) when using ubiquitous promoters such as human cytomegalovirus (CMV) or chicken-β-actin hybrid (CAG). To enhance targeting the transgene...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
